Welcome, Guest. Please login or register.
February 02, 2023, 04:06:30 pm

Login with username, password and session length

  • Total Members: 6292
  • Latest: DianeM1
  • Total Posts: 55090
  • Total Topics: 4846
  • Online Today: 51
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 21
Total: 21


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Recent Posts

Pages: 1 ... 8 9 [10]
Advanced Liver Disease / FDA Approves Tecentriq Plus Avastin for Liver Cancer
« Last post by Hep Editors on December 02, 2020, 11:39:07 am »
The Food and Drug Administration has approved a regimen combining the immune checkpoint inhibitor Tecentriq (atezolizumab) and the targeted therapy Avastin (bevacizumab) for the treatment of people with inoperable or metastatic hepatocellular carcinoma, the most common type of liver cancer.

In the Phase III IMbrave150 study, Tecentriq plus Avastin reduced the risk of disease progression or death by 41%, prolonged overall survival and improved quality of life compared with standard-of-care treatment.

Compared with the general population, hepatitis C virus (HCV) rates are substantially higher among men who have sex with men (MSM), in particular those living with HIV as well as HIV-negative men taking pre-exposure prophylaxis (PrEP), NATAP reports.

Presenting their findings at the International AIDS Conference (AIDS 2020), which was held virtually last week, researchers at the University of New South Wales and the World Health Organization conducted a systematic review and meta-analysis of HCV rates among MSM compared with the general population.

A combination of two antiviral drugs commonly used to treat hepatitis C virus (HCV) were found to shorten the duration of hospitalization and improve survival for people with moderate or severe COVID-19 in a set of studies in Iran, researchers reported at the virtual International AIDS Conference last week.

If larger studies now underway confirm these findings, sofosbuvir and daclatasvir could offer an affordable and widely accessible treatment option, study coauthor Andrew Hill, MD, of Liverpool University said at a press briefing.

The Food and Drug Administration (FDA) indicated in late June that it would not approve Intercept Pharmaceuticals’ Ocaliva (obeticholic acid) for the treatment of fibrosis related to non-alcoholic steatohepatitis until more data are available, the company announced. This delays the debut of a first approved therapy for the increasingly common and potentially serious liver condition.

However, as Arun Sanyal, MD, of Virginia Commonwealth University noted at a fatty liver disease symposium sponsored by the Nutrition Obesity Research Center at Harvard, if the agency thought the drug was “ineffective or toxic,” they likely would have stopped an ongoing clinical trial of the drug.

All right!!! Great news so happy to hear you made it to 24 weeks SVR.

Enjoy your hep c FREEDOM!!!!!
UPDATE!!!! Just got my 24 week post-treatment labs done and I am UNDETECTED!!!! I hope this brings some relief and hope to those out there still testing DETECTED 12 weeks after the end of treatment. I am beyond thrilled! Was seriously contemplating that something was wrong with me or that I had some type of immune issue. Here I am, 24 weeks post treatment and a big fat UNDETECTED!!!
Women are less likely to develop non- fatty liver disease (NAFLD) than their male counterparts. But women with NAFLD were more likely to progress to non-alcoholic steatohepatitis (NASH) and fibrosis than men with the condition, according to a meta-analysis study published in Clinical Gastroenterology and Hepatology.

“Our findings indicate that once NAFLD is established, the risk of progressive disease (i.e., NASH and advanced fibrosis) is not different and may be slightly higher among women than men,” reported the study authors.

Advanced Liver Disease / Hepatitis C–Infected Livers Can Be Safely Transplanted
« Last post by Hep Editors on November 06, 2020, 10:41:02 am »
Interim results from an ongoing study have indicated that people can safely receive liver transplants from donors with hepatitis C virus (HCV). Transplant outcomes are similar regardless of whether the donor liver was infected with HCV.

Researchers at the University of Cincinnati Medical Center established a cohort of 64 people who needed a liver transplant and divided them into two even groups. One group received livers from donors with hep C; the other group received livers from HCV-negative donors.

The transplants took place between June and October 2018.

People newly diagnosed with HIV are subsequently tested for hepatitis C virus (HCV) at a suboptimal rate.

Guidelines recommend that all people living with HIV receive hep C testing.

Investigators reached this conclusion by analyzing data from the 2003 to 2017 IBM Watson Health MarketScan database, which included information on 46,277 people newly diagnosed with HIV during that time. The study authors published their findings in Open Forum Infectious Diseases.

For more...
Almost a quarter of lean people living with HIV had evidence of nonalcoholic fatty liver disease (NAFLD) in a recent study, and nearly one in five of them developed substantial liver fibrosis, putting them at higher risk for cirrhosis and liver cancer, according to a recent study.

NAFLD and its more severe form, nonalcoholic steatohepatitis (NASH), are responsible for a growing proportion of advanced liver disease worldwide, and studies have shown that the condition is common among people living with HIV. Although often associated with obesity and metabolic syndrome—a constellation of cardiovascular risk factors including abnormal blood sugar and blood fat levels, hypertension (high blood pressure) and increased abdominal girth—fatty liver disease can also occur in people of normal weight.

Pages: 1 ... 8 9 [10]

© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.